Acta Neurol Scand 2001 Aug;104(2):88-91
Sindern E, Niederkinkhaus Y, Henschel
M, Ossege LM, Patzold T, Malin JP
Departments of Neurology, Radiology,
BG-Kliniken Bergmannsheil, Ruhr-University Bochum, FRG.
OBJECTIVE:
beta-chemokines were recently demonstrated
in active MS-lesions. We tested whether MCP-1 and RANTES can also be detected
in CSF and serum of patients with MS and whether release is associated
with inflammatory disease activity.
MATERIALS AND METHODS:
CSF and serum from 34 patients with
newly diagnosed relapsing-remitting MS (RR-MS), 17 patients with viral
meningitis (VM) and 19 patients with non-inflammatory neurological diseases
(NIND) were investigated by ELISA. RR-MS patients underwent lumbar puncture
and Gd-enhanced MRI examinations within 2 days.
RESULTS:
MCP-1 was strong intrathecally released
in all patients. Compared to NIND CSF-levels were increased in VM (P<0.001)
and were decreased in RR-MS (P<0.05). RANTES was only detected in serum
in all patients. Levels were higher in VM and RR-MS compared to NIND (P<0.05).
A total of 14/34 RR-MS patients exhibited active Gd-enhancing lesions on
MRI. They had lower MCP-1 levels in CSF (P<0.001) and serum (P<0.05)
and higher serum levels of RANTES (P<0.05) as compared to patients without
active lesions.
CONCLUSIONS:
MCP-1 and RANTES are differentially
released during acute attacks of RR-MS, which might reflect different immunregulatory
roles of these beta-chemokines in RR-MS.
PMID: 11493224, UI: 21384453